{
    "4 25 2025": {
        "importantArticles": [
            {
                "headline": "RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?",
                "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-report-q1-earnings-151600127.html"
            },
            {
                "headline": "RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?",
                "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-report-q1-earnings-151600127.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": 0.01957297789223378
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "3 Monster Stocks to Hold for the Next 10 Years",
                "url": "https://finance.yahoo.com/news/3-monster-stocks-hold-next-134500368.html"
            },
            {
                "headline": "They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "3 Monster Stocks to Hold for the Next 10 Years",
                "url": "https://finance.yahoo.com/news/3-monster-stocks-hold-next-134500368.html"
            }
        ],
        "avgScore": 0.3818,
        "pctChange": 0.030465963910092098
    },
    "4 22 2025": {
        "importantArticles": [
            {
                "headline": "Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6908",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025",
                "url": "https://finance.yahoo.com/news/recursion-present-preliminary-clinical-data-003400160.html"
            },
            {
                "headline": "Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6908",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025",
                "url": "https://finance.yahoo.com/news/recursion-present-preliminary-clinical-data-003400160.html"
            }
        ],
        "avgScore": 0.6908,
        "pctChange": -0.008881028369184767
    },
    "4 21 2025": {
        "importantArticles": [
            {
                "headline": "Recursion Pharmaceuticals (RXRX) reachead $5.41 at the closing of the latest trading day, reflecting a -1.64% change compared to its last close.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know",
                "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-stock-moves-215032641.html"
            },
            {
                "headline": "Recursion Pharmaceuticals (RXRX) reachead $5.41 at the closing of the latest trading day, reflecting a -1.64% change compared to its last close.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know",
                "url": "https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-stock-moves-215032641.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": 0.040665484886112595
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "PR Newswire",
                "ticker": "RXRX",
                "title": "HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data",
                "url": "https://finance.yahoo.com/news/healthverity-partners-recursion-enhance-clinical-123000357.html"
            },
            {
                "headline": "HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "PR Newswire",
                "ticker": "RXRX",
                "title": "HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data",
                "url": "https://finance.yahoo.com/news/healthverity-partners-recursion-enhance-clinical-123000357.html"
            }
        ],
        "avgScore": 0.4404,
        "pctChange": 0.03383455310724381
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Tech Firms Dominate Monday\u2019s 10 Worst Performers. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other tech firms that dominate Monday\u2019s worst performers. Wall Street\u2019s main indices kicked off the trading week in the green territory, albeit with minimal gains, [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8316",
                "source": "Insider Monkey",
                "ticker": "RXRX",
                "title": "Why Recursion Pharmaceuticals, Inc.\u00a0(RXRX) Went Down On Monday?",
                "url": "https://finance.yahoo.com/news/why-recursion-pharmaceuticals-inc-rxrx-050751253.html"
            },
            {
                "headline": "We recently published a list of Tech Firms Dominate Monday\u2019s 10 Worst Performers. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other tech firms that dominate Monday\u2019s worst performers. Wall Street\u2019s main indices kicked off the trading week in the green territory, albeit with minimal gains, [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8316",
                "source": "Insider Monkey",
                "ticker": "RXRX",
                "title": "Why Recursion Pharmaceuticals, Inc.\u00a0(RXRX) Went Down On Monday?",
                "url": "https://finance.yahoo.com/news/why-recursion-pharmaceuticals-inc-rxrx-050751253.html"
            }
        ],
        "avgScore": -0.8316,
        "pctChange": -0.056737535886435646
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC\u2019s Squawk on the Street, Jim [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "RXRX",
                "title": "Jim Cramer on Recursion (RXRX): \u201cThe AI Company That Has It \u2013 Backed by Jensen Huang and NVIDIA\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html"
            },
            {
                "headline": "Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1098",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?",
                "url": "https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html"
            },
            {
                "headline": "Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1098",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?",
                "url": "https://finance.yahoo.com/news/strength-seen-recursion-pharmaceuticals-rxrx-130900685.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC\u2019s Squawk on the Street, Jim [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "RXRX",
                "title": "Jim Cramer on Recursion (RXRX): \u201cThe AI Company That Has It \u2013 Backed by Jensen Huang and NVIDIA\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-recursion-rxrx-ai-193510944.html"
            }
        ],
        "avgScore": -0.0549,
        "pctChange": 0.023593399673985323
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.  The big gain for the biotech stock came after the U.S. Food and Drug Administration (FDA) announced on Thursday that it plans to replace the use of animals in testing drugs with \"more effective, human-relevant methods,\" including artificial intelligence (AI) models.  What will the FDA's move mean for Recursion?",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.902",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Recursion Pharmaceuticals Stock Is Skyrocketing Today",
                "url": "https://finance.yahoo.com/news/why-recursion-pharmaceuticals-stock-skyrocketing-151129734.html"
            },
            {
                "headline": "Julie Hyman and Josh Lipton take a closer look at some of today's trending tickers. Recursion Pharma (RXRX) stock surges after the Food and Drug Administration (FDA) announced plans to phase out some animal testing requirements. Intel (INTC) stock falls as tensions in the US-China trade war intensify. Five Below (FIVE) stock declines as China tariffs impact orders. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7951",
                "source": "Yahoo Finance Video",
                "ticker": "RXRX",
                "title": "Recursion Pharma rises, Intel & Five Below fall: Trending Tickers",
                "url": "https://finance.yahoo.com/video/recursion-pharma-rises-intel-five-194742139.html"
            },
            {
                "headline": "Julie Hyman and Josh Lipton take a closer look at some of today's trending tickers. Recursion Pharma (RXRX) stock surges after the Food and Drug Administration (FDA) announced plans to phase out some animal testing requirements. Intel (INTC) stock falls as tensions in the US-China trade war intensify. Five Below (FIVE) stock declines as China tariffs impact orders. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7951",
                "source": "Yahoo Finance Video",
                "ticker": "RXRX",
                "title": "Recursion Pharma rises, Intel & Five Below fall: Trending Tickers",
                "url": "https://finance.yahoo.com/video/recursion-pharma-rises-intel-five-194742139.html"
            },
            {
                "headline": "Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday.  The big gain for the biotech stock came after the U.S. Food and Drug Administration (FDA) announced on Thursday that it plans to replace the use of animals in testing drugs with \"more effective, human-relevant methods,\" including artificial intelligence (AI) models.  What will the FDA's move mean for Recursion?",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.902",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Recursion Pharmaceuticals Stock Is Skyrocketing Today",
                "url": "https://finance.yahoo.com/news/why-recursion-pharmaceuticals-stock-skyrocketing-151129734.html"
            }
        ],
        "avgScore": 0.05345,
        "pctChange": -0.04340277605310641
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world\u2019s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized co",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries",
                "url": "https://finance.yahoo.com/news/recursion-enamine-release-ai-enabled-120000336.html"
            },
            {
                "headline": "Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study",
                "url": "https://finance.yahoo.com/news/rxrx-doses-first-patient-early-140100723.html"
            },
            {
                "headline": "Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "RXRX",
                "title": "RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study",
                "url": "https://finance.yahoo.com/news/rxrx-doses-first-patient-early-140100723.html"
            },
            {
                "headline": "Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world\u2019s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized co",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries",
                "url": "https://finance.yahoo.com/news/recursion-enamine-release-ai-enabled-120000336.html"
            }
        ],
        "avgScore": 0.2202,
        "pctChange": -0.03010749755146688
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas",
                "url": "https://finance.yahoo.com/news/recursion-announces-first-patient-dosed-120000229.html"
            },
            {
                "headline": "REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas",
                "url": "https://finance.yahoo.com/news/recursion-announces-first-patient-dosed-120000229.html"
            }
        ],
        "avgScore": 0.128,
        "pctChange": 0.1712846503417403
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study.  Finally, the resignation of a key Federal Food and Drug Administration (FDA) regulator toward the end of the month cast a pall over the FDA approval process under the tenure of new Secretary of Health and Human Services, Robert F. Kennedy Jr.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March",
                "url": "https://finance.yahoo.com/news/why-biotech-stocks-biohaven-recursion-133000250.html"
            },
            {
                "headline": "Recursion Pharmaceuticals\u2014a relatively small company backed by the chip giant Nvidia\u2014is betting that its massive supercomputer will give it the edge to dominate the sector.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Fortune",
                "ticker": "RXRX",
                "title": "Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market",
                "url": "https://finance.yahoo.com/news/ai-ever-cure-cancer-multibillion-100000488.html"
            },
            {
                "headline": "Recursion Pharmaceuticals\u2014a relatively small company backed by the chip giant Nvidia\u2014is betting that its massive supercomputer will give it the edge to dominate the sector.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Fortune",
                "ticker": "RXRX",
                "title": "Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market",
                "url": "https://finance.yahoo.com/news/ai-ever-cure-cancer-multibillion-100000488.html"
            },
            {
                "headline": "The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study.  Finally, the resignation of a key Federal Food and Drug Administration (FDA) regulator toward the end of the month cast a pall over the FDA approval process under the tenure of new Secretary of Health and Human Services, Robert F. Kennedy Jr.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March",
                "url": "https://finance.yahoo.com/news/why-biotech-stocks-biohaven-recursion-133000250.html"
            }
        ],
        "avgScore": 0.0618,
        "pctChange": -0.11850315560128521
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference \u2014 Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ: RXRX) is a clinical stage Tech",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion to Participate in Upcoming Investor Conference",
                "url": "https://finance.yahoo.com/news/recursion-participate-upcoming-investor-conference-120000585.html"
            },
            {
                "headline": "Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference \u2014 Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ: RXRX) is a clinical stage Tech",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "GlobeNewswire",
                "ticker": "RXRX",
                "title": "Recursion to Participate in Upcoming Investor Conference",
                "url": "https://finance.yahoo.com/news/recursion-participate-upcoming-investor-conference-120000585.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": 0.0382728517549246
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies.  Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today",
                "url": "https://finance.yahoo.com/news/why-biotech-stocks-recursion-pharmaceuticals-192505216.html"
            },
            {
                "headline": "All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced technologies.  Over the weekend, Dr. Peter Marks, who headed the FDA's Center for Biologics Evaluation and Research, as well as its vaccine division, resigned in protest.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Motley Fool",
                "ticker": "RXRX",
                "title": "Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today",
                "url": "https://finance.yahoo.com/news/why-biotech-stocks-recursion-pharmaceuticals-192505216.html"
            }
        ],
        "avgScore": 0.0258,
        "pctChange": -0.03686203649670171
    },
    "coef": 0.09944903161976938,
    "avgCoef": -0.026323165572498478,
    "similar": {
        "SMMT": 0.6077440821208128,
        "LCID": 0.5469696739087315,
        "VALE": 0.480670319495552,
        "NKE": 0.480670319495552
    }
}